Children with spinal muscular atrophy (SMA) have shown promising motor function improvements when transitioning to onasemnogene abeparvovec after receiving prior treatment with nusinersen or risdiplam, as revealed in a recent real-world study. This study, published in Neuromuscular Disorders, highlighted the significant motor function enhancement observed in SMA patients who shifted to onasemnogene abeparvovec following initial treatments with nusinersen or risdiplam, indicating the potential benefits of gene therapy in this patient population. The study also emphasized the manageable safety profile associated with onasemnogene abeparvovec, further supporting the consideration of gene therapy for SMA patients who have undergone previous non-gene therapy treatments.
The retrospective analysis conducted at a single center included older and heavier children than those typically enrolled in pivotal trials, aligning more closely with real-world scenarios. These findings reflect the evolving landscape of SMA treatment, where onasemnogene abeparvovec therapy is increasingly initiated later due to various constraints such as treatment availability or funding delays. The study underlines the importance of understanding which patients might derive the most benefit from transitioning to gene therapy after initial non-gene therapy treatments, shedding light on the complexities of treatment decisions in SMA management.
In recent years, the treatment paradigm for SMA has witnessed significant transformations with the introduction of disease-modifying therapies like nusinersen and risdiplam, both of which aim to increase the production of survival motor neuron (SMN) protein crucial for SMA patients. On the other hand, onasemnogene abeparvovec provides a functional copy of the SMN1 gene through a one-time intravenous injection. While traditionally approved for children under 2 years, recent phase 3 data have displayed promising efficacy and safety in older children with SMA, expanding the therapeutic possibilities for a broader age range.
Emerging strategies in SMA treatment include combining therapies like nusinersen or risdiplam with gene therapy for a transitional period or switching to gene therapy after prolonged use of these non-gene therapies. The study emphasizes that earlier intervention, typically in younger and lighter patients, correlates with more substantial improvements in motor function scales, underscoring the importance of timely treatment initiation in maximizing therapeutic outcomes for SMA patients. The analysis evaluated motor and safety outcomes in SMA children who transitioned to gene therapy post-nusinersen or risdiplam treatment, demonstrating notable improvements in motor function scores within a relatively short timeframe.
Key Takeaways:
– Transitioning to gene therapy with onasemnogene abeparvovec after nusinersen or risdiplam treatment can lead to meaningful motor function improvements in SMA patients.
– Early intervention with gene therapy may result in more significant motor function gains, highlighting the importance of timely treatment initiation in SMA management.
– While the safety profile of onasemnogene abeparvovec remains manageable, considerations regarding patient selection for therapy transitions are crucial for optimizing treatment outcomes.
– Combination strategies involving gene therapy alongside existing SMA treatments present a promising approach to enhance therapeutic efficacy and patient outcomes.
Tags: gene therapy, precision oncology
Read more on ajmc.com